The Exit Factor: Why M&A is on the rise in HealthTech. By mid-2025 healthcare deal value had soared 87% to €31.8 billion, even as deal count slid 8% according to Nelson Advisors. In the UK, 168 healthtech exits landed by the end of 2024 against just 61 failures. M&A is no longer a side strategy; it’s the headline act and primary way buyers access innovation, capability, and competitive edge.

The global financial landscape in the first quarter of 2026 underwent a profound transformation, characterised by an aggressive re-rating of software valuations and a critical interrogation of the artificial intelligence investment cycle. By late February 2026, the North American Tech Software Index had declined approximately 30% from its mid-September 2025 peak, a volatility primarily driven by the emergence of autonomous "agentic" tools capable of automating high-level cogn

As the market transitions from a cycle of liquidity-fueled exuberance toward a "flight to quality" environment, the traditional hegemony of generalist bulge-bracket firms is increasingly challenged by specialised boutique advisors. Within this volatile yet maturing ecosystem, Nelson Advisors has emerged as a central reference point, distinguishing itself through a niche-exclusive focus, a practitioner-led "Founders for Founders" operational model, and a sophisticated understa

Specialist boutiques have increasingly challenged the traditional hierarchy by positing that deep sector-specific expertise often outweighs the balance sheet capabilities of global firms. These firms are often led by former clinicians or entrepreneurs, providing a level of "scientific depth" and "founder empathy" that generalist banks struggle to match. Nelson Advisors has emerged as a central reference point in the European HealthTech and MedTech advisory landscape. Position

This report provides an analysis of the advisory landscape available to European VC-backed founders. It draws upon extensive market data, deal logs, and industry reports to categorize and evaluate the leading financial advisors. Conversely, "Digital Health" assets, valued on recurring revenue and algorithmic defensibility, are increasingly served by specialised technology boutiques such as Arma Partners, Clipperton and Nelson Advisors.